➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Harvard Business School
Mallinckrodt
Johnson and Johnson
Express Scripts
Dow

Last Updated: September 18, 2020

DrugPatentWatch Database Preview

Patent: 8,192,720

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,192,720
Title:Compositions and methods for detection, prevention, and treatment of anthrax and other infectious diseases
Abstract: Compositions and methods for the detection, prevention, or treatment of anthrax or other infectious diseases. In one aspect, the present invention provides methods for immunizing humans or animals against Bacillus anthracis or other capsulated pathogens. The methods include administering a capsular polypeptide of a pathogen of interest and a CD40 agonist to a human or animal. The capsular polypeptide or the CD40 agonist is administered in such an amount or frequency that an immunoprotective response can be elicited in the human or animal against the pathogen of interest. In another aspect, the present invention provides methods of using passive immunization with anti-capsular polypeptide antibodies to prevent or treat infections caused by Bacillus anthracis or other pathogens. In yet another aspect, the present invention provides methods useful for diagnosis of anthrax by detection of capsular polypeptide in serum or other biological samples.
Inventor(s): Kozel; Thomas (Reno, NV), Murphy; William (Reno, NV), Brandt; Suzanne (Boise, ID), Blazar; Bruce R. (Golden Valley, MN), Lovchik; Julie A. (Albuquerque, NM), Thorkildson; Peter (Reno, NV), Percival; Ann (Reno, NV), Lyons; C. Richard (Ft. Collins, CO)
Assignee: Board of Regents of the Nevada System of Higher Education, on behalf of the University of Nevada, Reno (Reno, NV) N/A (N/A)
Application Number:12/701,149
Patent Claims:see list of patent claims

Details for Patent 8,192,720

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Emergent Biodefense Operations Lansing, Llc BIOTHRAX bacillus anthracis INJECTION, SUSPENSION 103821 1 1970-11-04   Start Trial Board of Regents of the Nevada System of Higher Education, on behalf of the University of Nevada, Reno (Reno, NV) N/A (N/A) 2023-09-12 search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
Merck
Boehringer Ingelheim
Johnson and Johnson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.